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Book Reviews
Baruch A. Brody, Ethical Issues in Drug Testing, Approval, and Pricing
(Oxford University Press 1995). Conclusions, index, introduction, preface. LC
94-4479; ISBN 0-19-508831-X. [268 pp. Cloth $35.00. 200 Madison Avenue, New
York NY 10016.]

Dr. Brody presents an encyclopedic chronology of the clinical trial
sequence which led to the approval of thrombolytic agents that dissolve
clots in coronary arteries. A member of an Institutional Review Board
(IRB) that dealt with streptokinase and tPA thrombolitic agents, he
uses this experience to shed light on ethical issues involved in drug
development. Readers gain an understanding of how the interdigitating
roles of the Food and Drug Administration (FDA), National Institutes
of Health, Health Care Finance Administration, pharmaceutical
industry, hospitals, physicians, investors and journalists play out against
the background of science, the economy, medical ethics and patent law.
Ethical issues regarding streptokinase and tPA are magnified and
methodically analyzed. Brody weighs the scientific merit of placebo
controlled studies against risks and benefits of the drugs to individual
patients. He demonstrates that the risk-benefit ratio continually alters
as further information about the drugs' safety and efficacy becomes
available and is factored into the equation.
A section on informed consent includes thoughtful discussion of the
Nuremberg Code and Declaration of Helsinki. These provide a
philosophical basis to remind us of the necessity for a responsible and
informed consent. A history of informed consent, its current relevancy
and circumstances when it is not needed are included.
Brody's conflict of interest section is refreshing. It acknowledges
that double-masked studies using objective criteria, when well
controlled and properly executed, dramatically limit the potential for
biased results. However, the author does not acknowledge the role of
the IRB and the FDA in reviewing study design and execution as
further protection of integrity. He feels that stock ownership and
consulting agreements by investigators, while creating the perception of
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conflicts, are unlikely to lead to biased results. Brody finds investigator
grants or per capita reimbursement, the usual means by which
investigators are remunerated, as having more potential for fostering
conflicts of interest but proposes no satisfactory alternative.
Readers are also encouraged to think about the justice of health
resource allocation, and a two tiered system is suggested: One with
reasonable basic benefits, the other for those who choose to use their
wealth to obtain more expensive, only marginally more efficient, drugs.
Brody challenges readers to put a price on life to evaluate whether we
should be using very expensive drugs that enhance survival by a small
percentage. He relates this to using tPA over streptokinase where tPA is
ten times the price.
In this regard it would have been good to have seen some mention
of the new field of pharmacoeconomics which attempts to place an
objective value on an agent according to benefits derived from its use.
Also, while Brody shows that pricing in other countries is directly
related to the number of new drugs developed, he advances socializing
the pharmaceutical industry without apparent recognition that a free
market economy is most likely propulsion behind drug development.
Ethical Issues deals thoughtfully with critical ethical issues in drug
development. It is well organized, readable and informative. While
there will always be excitement surrounding the prospects of new
agents, investigators can never forget that they are dealing with the
unknown consequences of new chemicals. Patients have rights; anyone
involved in drug development must consider those rights and will find
this book a scholarly approach to the subject.
Annalee Abelsont
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